You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 Overexpression

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin
  • +3 more
  • (no location specified)
Nov 17, 2022

Gastric Cancer Trial (Disitamab Vedotin Combined With Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin Combined With Sintilimab
  • (no location specified)
Jan 31, 2023

Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)

Completed
Has Results
  • Breast Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 20, 2022

Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

Not yet recruiting
  • Esophageal Squamous Carcinoma
  • HER-2 Protein Overexpression
  • (no location specified)
Sep 24, 2023

Non Small Cell Lung Cancer Trial in Shanghai (RC48)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jan 26, 2022

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • Dnipro, Ukraine
  • +1 more
Jun 17, 2023

HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +3 more
  • San Antonio, Texas
  • +1 more
Aug 22, 2022

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in Beijing (RC48-ADC)

Completed
  • Gastric Cancer
  • HER2 Overexpressing Gastric Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2022

Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in Copenhagen, Odense

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Copenhagen, Region H, Denmark
  • +1 more
Aug 10, 2022

HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen

Recruiting
  • HER-2 Gene Amplification
  • +4 more
  • chimeric antigen receptor (CAR) T cell therapy
  • Duarte, California
  • +6 more
Aug 10, 2022

Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression Trial in New York, Providence (Nivolumab, Trastuzumab

Not yet recruiting
  • Esophageal Adenocarcinoma
  • +3 more
  • New York, New York
  • +1 more
Jul 28, 2022

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in China (RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride

Recruiting
  • Gastric Cancer
  • HER2 Overexpressing Gastric Carcinoma
  • Beijing, Beijing, China
  • +51 more
Jan 6, 2022

Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

Recruiting
  • Sarcoma
  • HER-2 Protein Overexpression
  • cells
  • +3 more
  • Houston, Texas
    Texas Children's Hospital
Dec 8, 2021

HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)

Recruiting
  • HER2-positive
  • +30 more
  • CT-0508
  • Duarte, California
  • +4 more
Feb 1, 2022

HER2-positive Breast Cancer, HER2 Low, SYD-985 Trial in Aurora (Vic-trastuzumab duocarmazine (SYD985) + paclitaxel)

Recruiting
  • HER2-positive Breast Cancer
  • +26 more
  • Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
  • Aurora, Colorado
    University of Colorado Cancer Center
Oct 22, 2021

Cholangiocarcinoma, Biliary Tract Cancer, HER-2 Protein Overexpression Trial in Seoul (Trastuzumab)

Completed
  • Cholangiocarcinoma
  • +3 more
  • Seoul, Korea, Republic of
    Asan Medical Center
Jan 4, 2021

HER2-overexpressed Advanced Solid Tumors After Progression of

Not yet recruiting
  • HER2
  • +3 more
  • Disitamab Vedotin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 14, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

Active, not recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 23, 2023

Breast Cancer Trial in Los Angeles (trastuzumab, erlotinib HCl)

Completed
Has Results
  • Breast Cancer
  • trastuzumab
  • erlotinib hydrochloride
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center at UCLA
Sep 17, 2020

Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer Trial (SNK01, Trastuzumab, Cetuximab)

Withdrawn
  • Advanced Solid Tumor
  • +16 more
  • SNK01
  • +2 more
  • (no location specified)
May 10, 2021

Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Portland, Suwon (AB-201, Cyclophosphamide,

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Portland, Oregon
  • +1 more
Jan 12, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Not yet recruiting
  • Urothelial Carcinoma
    • (no location specified)
    Jun 5, 2023